Immune checkpoint blockade (ICB) therapy, especially using PD-1 monoclonal antibodies (anti-PD-1), has emerged as a cornerstone in cancer immunotherapy because of its remarkable clinical efficacy (1, 2). Here, PDCD1 is linked to cancer.